DAVID BENHAYON: Open Payments
NPI 1083824130 · INDIANA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$599 in 30 payments from 12 companies in 2025. Trend: 2023 $1,628 · 2024 $870 · 2025 $599
Food & beverage: $599
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| Lundbeck LLC | 3 | $71 |
| Neurocrine BioSciences, Inc. | 3 | $55 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Alkermes, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| ABBVIE INC. | 1 | $22 |
Products named: REXULTI, UZEDY, INGREZZA, Jornay PM, CAPLYTA, INVEGA SUSTENNA, ARISTADA, ABILIFY MAINTENA.
Industry payments across PA — which companies pay providers there.
